Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,153
archived clinical trials in
Gout

Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated:  11/13/2015
Clinical Research Facility
mi
from
Escondido, CA
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Status: Enrolling
Updated: 11/13/2015
Clinical Research Facility
mi
from
Escondido, CA
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Birmingham, AL
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Louisville, KY
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Metairie, LA
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Metairie, LA
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Jackson, MS
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Jackson, MS
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Albuquerque, NM
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
New York, NY
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Dallas, TX
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Seattle, WA
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Glendale, AZ
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Glendale, AZ
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Tucson, AZ
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Jonesboro, AR
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Little Rock, AR
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Anaheim, CA
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Carmichael, CA
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Carmichael, CA
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Covina, CA
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Covina, CA
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Huntington Park, CA
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Huntington Park, CA
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Irvine, CA
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Irvine, CA
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Colorado Springs, CO
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Denver, CO
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Englewood, CO
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Englewood, CO
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Milford, CT
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Milford, CT
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Trumbull, CT
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Trumbull, CT
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Boynton Beach, FL
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Jacksonville, FL
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Miami, FL
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Plant City, FL
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Plant City, FL
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Port Orange, FL
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Port Orange, FL
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Tampa, FL
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Winter Haven, FL
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Winter Haven, FL
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Newman, GA
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Newman, GA
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Honolulu, HI
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Honolulu, HI
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Meridian, ID
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Meridian, ID
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Chicago, IL
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Elizabethtown, KY
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Elizabethtown, KY
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Lexington, KY
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
mi
from
South Traverse, MI
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
mi
from
South Traverse, MI
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Olive Branch, MS
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Olive Branch, MS
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
mi
from
Southfield, MO
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
mi
from
Southfield, MO
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Washington, MO
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Washington, MO
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Brooklyn, NY
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Hartsdale, NY
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Hartsdale, NY
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
New Windsor, NY
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
New Windsor, NY
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Hickory, NC
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Hickory, NC
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Raleigh, NC
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Winston-Salem, NC
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Fargo, ND
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Fargo, ND
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated:  1/14/2016
mi
from
Middleburgh Heights, OH
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor
Status: Enrolling
Updated: 1/14/2016
mi
from
Middleburgh Heights, OH
Click here to add this to my saved trials